CRISPR | CHOP Research Institute


Published on
Feb 3, 2023
In this news roundup, we celebrate research tools new and old, from RNA sequencing to gene editing to the best tool of all: collaboration.
Published on
Jun 24, 2022
This week’s In the News features endocrinology research, news on gene therapy in blood disorders, CAR T-cell therapy, and more.
Published on
Dec 20, 2021
Dr. Carpenter’s research seeks to better understand how environmental factors affect the origins of disease via epigenetic modifications.

Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.

bailisw [at]
Published on
May 24, 2021
A previously unreported immunodeficiency disease prevents the formation of the B cells and antibodies that help fight off infections.

The lab focuses on translational target discovery for a range of neurodegenerative diseases. We combine technology development of large-scale CRISPR-based perturbation screens with application of such technology together with additional genomic approaches.

The Gadue Lab studies human pancreatic and hematopoietic development and associated diseases using human pluripotent stem cells. The lab’s research efforts are devoted to directed differentiation and CRISPR-based genome engineering of stem cells to use in the study and development of treatments for diabetes and blood disorders.

All biological processes operate under biochemical constraints. The Bailis Lab aims to understand how metabolism controls the development and functional differentiation of the hematopoietic system by setting the biochemical potential of cells and tissues, using in vitro and in vivo CRISPR screening in primary immune cells.

Published on
May 20, 2020
A CHOP scientist is leveraging her expertise in CRISPR-based genetic screens to contribute to our understanding of COVID-19’s pathology.
Published on
Mar 11, 2020
With a new NIH Innovator Award, Ophir Shalem, PhD, is developing an improved genetic screening method that directly targets proteins.